Brokerages predict that Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) will announce $16.32 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Kiniksa Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $16.13 million and the highest estimate coming in at $16.51 million. The company is scheduled to report its next quarterly earnings results on Tuesday, February 22nd.
On average, analysts expect that Kiniksa Pharmaceuticals will report full-year sales of $36.12 million for the current fiscal year, with estimates ranging from $35.93 million to $36.30 million. For the next financial year, analysts forecast that the company will post sales of $127.24 million, with estimates ranging from $114.54 million to $139.93 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Monday, November 1st. The company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.21. The company had revenue of $12.10 million for the quarter, compared to the consensus estimate of $9.92 million.
Shares of NASDAQ KNSA traded up $0.33 during trading hours on Monday, hitting $12.13. 274,216 shares of the company traded hands, compared to its average volume of 439,208. The company has a market capitalization of $835.61 million, a PE ratio of -4.74 and a beta of -0.07. The firm’s 50 day moving average is $12.29. Kiniksa Pharmaceuticals has a 12 month low of $10.30 and a 12 month high of $24.70.
Several hedge funds have recently modified their holdings of the business. Macquarie Group Ltd. lifted its stake in shares of Kiniksa Pharmaceuticals by 1,207.2% during the 3rd quarter. Macquarie Group Ltd. now owns 4,353 shares of the company’s stock worth $50,000 after purchasing an additional 4,020 shares during the last quarter. BNP Paribas Arbitrage SA lifted its stake in shares of Kiniksa Pharmaceuticals by 424.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,633 shares of the company’s stock worth $64,000 after purchasing an additional 4,559 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Kiniksa Pharmaceuticals by 180.7% during the 1st quarter. Royal Bank of Canada now owns 5,701 shares of the company’s stock worth $105,000 after purchasing an additional 3,670 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth $115,000. Finally, Invesco Ltd. lifted its stake in shares of Kiniksa Pharmaceuticals by 15.9% during the 3rd quarter. Invesco Ltd. now owns 12,736 shares of the company’s stock worth $145,000 after purchasing an additional 1,751 shares during the last quarter. Institutional investors and hedge funds own 42.04% of the company’s stock.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404.
Featured Story: What is the CBOE Russell 2000® Volatility Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.